John H. Van Drie
John H. Van Drie
Van Drie Research LLC
vandrieresearch.com üzerinde doğrulanmış e-posta adresine sahip - Ana Sayfa
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease
J Erickson, DJ Neidhart, J VanDrie, DJ Kempf, XC Wang, DW Norbeck, ...
Science 249 (4968), 527-533, 1990
7311990
Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease
J Erickson, DJ Neidhart, J VanDrie, DJ Kempf, XC Wang, DW Norbeck, ...
Science 249 (4968), 527-533, 1990
7311990
Structure− activity landscape index: identifying and quantifying activity cliffs
R Guha, JH Van Drie
Journal of chemical information and modeling 48 (3), 646-658, 2008
2802008
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
LM Lasko, CG Jakob, RP Edalji, W Qiu, D Montgomery, EL Digiammarino, ...
Nature 550 (7674), 128-132, 2017
2652017
ALADDIN: An integrated tool for computer-assisted molecular design and pharmacophore recognition from geometric, steric, and substructure searching of three-dimensional …
JH Van Drie, D Weininger, YC Martin
Journal of Computer-Aided Molecular Design 3 (3), 225-251, 1989
2531989
Virtual screening in drug discovery
J Alvarez, B Shoichet
CRC press, 2005
1772005
Navigating structure–activity landscapes
J Bajorath, L Peltason, M Wawer, R Guha, MS Lajiness, JH Van Drie
Drug discovery today 14 (13-14), 698-705, 2009
1612009
Pharmacophore discovery-lessons learned
JH van Drie
Current pharmaceutical design 9 (20), 1649-1664, 2003
1462003
Computer-aided drug design: the next 20 years
JH Van Drie
Journal of computer-aided molecular design 21 (10), 591-601, 2007
1212007
Approaches to virtual library design
JH Van Drie, MS Lajiness
Drug Discovery Today 3 (6), 274-283, 1998
1211998
Inhibitors of hepatitis C virus NS3· 4A protease 2. Warhead SAR and optimization
RB Perni, J Pitlik, SD Britt, JJ Court, LF Courtney, DD Deininger, ...
Bioorganic & Medicinal Chemistry Letters 14 (6), 1441-1446, 2004
852004
Assessing how well a modeling protocol captures a structure− activity landscape
R Guha, JH Van Drie
Journal of chemical information and modeling 48 (8), 1716-1728, 2008
802008
Bridged bicyclic serine protease inhibitors
LJ Farmer, J Pitlik, RB Perni, LF Courtney, J Van Drie
US Patent 6,909,000, 2005
692005
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
J Pitlik, KM Cottrell, LJ Farmer, RB Perni, LF Courtney, JH Van Drie, ...
US Patent 7,273,885, 2007
642007
Strategies for the determination of pharmacophoric 3D database queries
JH Van Drie
Journal of computer-aided molecular design 11 (1), 39-52, 1997
621997
Inhibitors of hepatitis C virus NS3· 4A protease. Part 3: P2 proline variants
RB Perni, LJ Farmer, KM Cottrell, JJ Court, LF Courtney, DD Deininger, ...
Bioorganic & medicinal chemistry letters 14 (8), 1939-1942, 2004
612004
Monty Kier and the origin of the pharmacophore concept
JH Van Drie
Internet Electron. J. Mol. Des 6 (9), 271-279, 2007
572007
Enhancement of binary QSAR analysis by a GA-based variable selection method
H Gao, MS Lajiness, J Van Drie
Journal of Molecular Graphics and Modelling 20 (4), 259-268, 2002
552002
Inhibitors of hepatitis C virus NS3· 4A protease 1. Non-Charged tetrapeptide variants
RB Perni, SD Britt, JC Court, LF Courtney, DD Deininger, LJ Farmer, ...
Bioorganic & Medicinal Chemistry Letters 13 (22), 4059-4063, 2003
542003
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
RB Perni, SD Britt, J Pitlik, JH Van Drie
US Patent 7,378,422, 2008
502008
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20